MRI characteristics of neuromyelitis optica spectrum disorder: an international update

HJ Kim, F Paul, MA Lana-Peixoto, S Tenembaum… - Neurology, 2015 - AAN Enterprises
Since its initial reports in the 19th century, neuromyelitis optica (NMO) had been thought to
involve only the optic nerves and spinal cord. However, the discovery of highly specific anti …

Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

B Banwell, JL Bennett, R Marignier, HJ Kim… - The Lancet …, 2023 - thelancet.com
Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in
patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis …

Myelin-oligodendrocyte glycoprotein antibody-associated disease

R Marignier, Y Hacohen, A Cobo-Calvo… - The Lancet …, 2021 - thelancet.com
Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently
identified autoimmune disorder that presents in both adults and children as CNS …

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis

M Duddy, M Niino, F Adatia, S Hebert… - The Journal of …, 2007 - journals.aai.org
Although recent animal studies have fuelled growing interest in Ab-independent functions of
B cells, relatively little is known about how human B cells and their subsets may contribute to …

[HTML][HTML] Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder

SJ Pittock, A Berthele, K Fujihara, HJ Kim… - … England Journal of …, 2019 - Mass Medical Soc
Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune,
inflammatory disorder that typically affects the optic nerves and spinal cord. At least two …

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

BAC Cree, JL Bennett, HJ Kim, BG Weinshenker… - The Lancet, 2019 - thelancet.com
Background No approved therapies exist for neuromyelitis optica spectrum disorder
(NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes …

Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis

A Bar‐Or, RK Nuttall, M Duddy, A Alter, HJ Kim… - Brain, 2003 - academic.oup.com
Matrix metalloproteinases (MMPs) are implicated in multiple sclerosis where one of their
roles may be to facilitate the transmigration of circulating leukocytes into the CNS. Studies …

A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder

SH Kim, SY Huh, SJ Lee, AR Joung, HJ Kim - JAMA neurology, 2013 - jamanetwork.com
Importance A previous 2-year analysis of repeated rituximab treatment in patients with
neuromyelitis optica (NMO) revealed significant improvements in relapse rates and …

Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years

SH Kim, W Kim, XF Li, IJ Jung, HJ Kim - Archives of neurology, 2011 - jamanetwork.com
Objective To evaluate the efficacy and safety of repeated rituximab treatment based on the
assessment of peripheral circulating memory B cells over 24 months in patients with …

Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography

JL Bennett, J de Seze, M Lana-Peixoto… - Multiple Sclerosis …, 2015 - journals.sagepub.com
Neuromyelitis optica (NMO) is an inflammatory autoimmune disease of the central nervous
system that preferentially targets the optic nerves and spinal cord. The clinical presentation …